Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sara Subzwari"'
Autor:
Lee M. Krug, Maria Catherine Pietanza, Naoko Takebe, Rosalyn A. Juergens, Mark G. Kris, Sara Subzwari, Naiyer A. Rizvi, Andrew Brown, William D. Travis, Paul K. Paik, Leonard James, Charles M. Rudin, Michelle S. Ginsberg, Susan Markus, Leslie B. Tyson
Publikováno v:
Lung Cancer. 74:481-485
We previously reported data on the safety, tolerability, and recommended phase II dose of obatoclax mesylate in conjunction with topotecan in patients with advanced solid tumor malignancies. Preliminary efficacy data suggested activity in patients wi
Autor:
Sara Subzwari, Michelle S. Ginsberg, Rosalyn A. Juergens, Leonard James, Susan Markus, William D. Travis, Lee M. Krug, Andrew Brown, Leslie B. Tyson, Naiyer A. Rizvi, Mark G. Kris, Charles M. Rudin, Naoko Takebe, Paul K. Paik
To establish the safety, maximum tolerated dose (MTD), recommended phase II dose, and preliminary antitumor activity of obatoclax mesylate (GX15-070MS), a Bcl-2 antagonist, in combination with topotecan in patients with solid tumor malignancies.Patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bdeb1527204bbbd3c78737cdb089e62
https://europepmc.org/articles/PMC2945625/
https://europepmc.org/articles/PMC2945625/
Autor:
Frank Sirotnak, Jyoti D. Patel, Michelle S. Ginsberg, Martha Huntington, Mark G. Kris, Jennifer May, Lee M. Krug, Sara Subzwari, Leslie B. Tyson, Leonard James, Michael Saunders, Christopher G. Azzoli, Vincent A. Miller, Megan Dunne
Publikováno v:
Journal of Thoracic Oncology. (11):1915-1922
Introduction Pralatrexate is an antifolate designed for preferential tumor cell uptake and accumulation and received accelerated Food and Drug Administration approval in relapsed/refractory peripheral T-cell lymphoma. Pralatrexate 135 to 150 mg/m 2 e